期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
Purpose Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptor (DR) 4 and DR5 and induces tumor-selective apoptosis. ......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (4)
Background Cytosolic phospholipase A2alpha (cPLA2 alpha), an enzyme that is responsible for the hydrolysis of membrane phospholipids, is a key mediato......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (3)
Purpose To compare the pharmacokinetic profiles, safety and immunogenicity of proposed bevacizumab biosimilar HLX04 with reference bevacizumab in heal......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (1)
Purpose The BRAF(V600E) mutation is an oncogenic driver associated with aggressive tumor behaviors and increased mortality among patients with papilla......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (1)
As the main substance in some traditional Chinese medicines, cucurbitacins have been used to treat hepatitis for decades in China. Currently, the use ......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
A correction to this paper has been published: http://fcb4e4bc18db4e2ead7856820ff3646c.ebe14e7a.libvpn.zuel.edu.cn/10.1007/s00280-021-04287-1
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (3)
Purpose This phase I trial was performed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), preliminary efficacy, and pha......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
Aim The present study aims to examine the effects of apatinib combined with autophagy inhibitor 3-Methyladenine (3-MA) on the proliferation and apopto......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (4)
Purpose This study aimed to investigate the possibility of UCP-2 inhibitor in reducing acquired resistance of trastuzumab to improve the outcome of pa......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
Purpose Tongue squamous cell carcinoma (TSCC) is the most common highly invasive oral cancer. Glaucocalyxin A (GLA) is a diterpenoid component isolate......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
Objectives Gemcitabine (Gem) is one of the most commonly used chemotherapeutic drugs in treating patients with pancreatic ductal adenocarcinoma (PDAC)......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
Purpose Limited value is achieved in systemic chemotherapy for oral squamous cell carcinoma (OSCC), due to cancer cell resistance against cytotoxic ag......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (2)
Purpose The poly(ADP-ribose) polymerase inhibitor rucaparib is approved for the treatment of patients with recurrent ovarian and metastatic castration......
期刊： CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (4)
Purpose We investigated the combination of tivantinib, a c-MET tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-VEGF-A antibody. Methods Pati......
